Patient Derived Xenograft/PDX Models Market worth 167.6 Million USD by 2022

1
MarketsandMarkets Presents
Patient Derived Xenograft/PDX Models Market worth
167.6 Million USD by 2022
http//www.marketsandmarkets.com/Market-Reports/pa
tient-derived-xenograft-model-market-121598251.htm
l
2
The report "Patient Derived Xenograft/PDX Models
Market by Type (Mouse Rat), Tumor Type
(Gastrointestinal, Gynecological, Respiratory),
Application (Pre-Clinical Drug Development
Biomarker Analysis), End User (Pharma Biotech,
CRO) - Global Forecast to 2022. Browse 44
market data tables,34 figures , 148 pages And
in-depth TOC on Patient Derived Xenograft/PDX
Models Market Get The PDF Brochure For This
Report http//www.marketsandmarkets.com/pdfdownl
oad.asp?id121598251 The PDX models market is
expected to reach USD 167.6 Million by 2022 from
an estimated USD 77.4 Million in 2017, at a CAGR
of 16.7. 
http//www.marketsandmarkets.com/Market-Reports/pa
tient-derived-xenograft-model-market-121598251.htm
l
3
The growth of the overall Patient Derived
Xenograft Models Market can be attributed to the
growing demand for personalized medicine,
continuous support for cancer research from the
public as well as private sectors, and growth in
the number of RD activities in the
pharmaceutical industry. In the coming years,
North America is expected to account for the
largest share of the global market. Base year
considered for the report is 2016 and the
forecast period includes 20172022. Drivers Gro
wing Demand for Personalized Medicine Continuous
Support for Cancer Research From Public as Well
as Private Sector Growth in the Number of
Pharmaceutical RD Activities Opportunity Risi
ng Demand for Humanized PDX Models Request a
sample of the report http//www.marketsandmarkets
.com/requestsample.asp?id121598251
http//www.marketsandmarkets.com/Market-Reports/pa
tient-derived-xenograft-model-market-121598251.htm
l
4
Industry Insights On the basis of tumor type,
the PDX models market has been segmented into
gastrointestinal tumor models, gynecological
tumor models, respiratory tumor models,
urological tumor models, hematological tumor
models, and other tumor models such as head
neck tumors, sarcoma, and melanoma. In 2017, the
gastrointestinal tumors segment is expected to
account for the largest share of the global PDX
models market. The respiratory tumors segment, on
the other hand, is expected to be the
fastest-growing segment during the forecast
period. Growth in this segment is mainly driven
by the increasing focus of market players on
generating lung cancer PDX models, which could
lead to a breakthrough in lung cancer treatment
as lung cancer is the leading cause of
cancer-related deaths across the globe. Based on
application, the PDX models market is further
segmented into the preclinical drug development
basic cancer research and biomarker analysis. In
2017, the preclinical drug development and basic
cancer research segment is expected to account
for the largest share of the global PDX models
market. The large share of this segment can be
mainly attributed to the increasing number of
research activities in the field of oncology drug
research.
http//www.marketsandmarkets.com/Market-Reports/pa
tient-derived-xenograft-model-market-121598251.htm
l
5

• On the basis of end user, the PDX models market
  has been segmented into pharmaceutical and
  biotechnology companies, contract research
  organizations (CROs), and academic research
  institutions. The pharmaceutical and
  biotechnology companies segment is estimated to
  account for the largest share of the patient
  derived xenograft models market in 2017.
• Target Audience
• Mice/rat models and service companies and
  distributors
• Animal care product manufacturers and suppliers
• Outlicensing life sciences companies
  (pharmaceutical/biopharmaceutical/biotechnology)
• Inlicensing life sciences companies
  (pharmaceutical/biopharmaceutical/biotechnology)
• Industry Leaders
• The various players in the PDX models market
  include Crown Bioscience Inc. (US), WuXi AppTec
  (China), Champions Oncology, Inc. (US), The
  Jackson Laboratory (US), ONCODESIGN (France),
  Charles River Laboratories International, Inc.
  (US), EPO Berlin-Buch GmBH (Germany), Shanghai
  LIDE Biotech Co., Ltd (China), Xentech (France),
  Horizon Discovery Group PLC (UK), Urolead
  (France), and Explora BioLabs (US).

6
About MarketsandMarkets MarketsandMarkets
provides quantified B2B research on 30,000 high
growth niche opportunities/threats which will
impact 70 to 80 of worldwide companies
revenues. Currently servicing 5000 customers
worldwide including 80 of global Fortune 1000
companies as clients. Almost 75,000 top officers
across eight industries worldwide approach
MarketsandMarkets for their painpoints around
revenues decisions.   Our 850 fulltime analyst
and SMEs at MarketsandMarkets are tracking
global high growth markets following the "Growth
Engagement Model GEM". The GEM aims at
proactive collaboration with the clients to
identify new opportunities, identify most
important customers, write "Attack, avoid and
defend" strategies, identify sources of
incremental revenues for both the company and its
competitors. MarketsandMarkets now coming up
with 1,500 MicroQuadrants (Positioning top
players across leaders, emerging companies,
innovators, strategic players) annually in high
growth emerging segments. MarketsandMarkets is
determined to benefit more than 10,000 companies
this year for their revenue planning and help
them take their innovations/disruptions early to
the market by providing them research ahead of
the curve.   MarketsandMarketss flagship
competitive intelligence and market research
platform, "RT" connects over 200,000 markets and
entire value chains for deeper understanding of
the unmet insights along with market sizing and
forecasts of niche markets.   
http//www.marketsandmarkets.com/Market-Reports/pa
tient-derived-xenograft-model-market-121598251.htm
l
7
Contact Us
Mr. Rohan MarketsandMarkets 701 Pike Street
Suite 2175, Seattle, WA 98101, United States
Tel [phone] Email sales_at_marketsandmarket
s.com MarketsandMarkets Bloghttp//www.marketsan
dmarkets.comhttp//twitter.com/marketsmarkets htt
p//www.linkedin.com/company/marketsandmarkets